Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: A pilot study of prescription-event monitoring in Japan

K. Samizo, E. Kawabe, S. Hinotsu, T. Sato, S. Kageyama, C. Hamada, Y. Ohashi, K. Kubota

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE inhibitors and dihydropyridine calcium channel antagonists. Study design: We conducted a cohort study with a concurrent control. Methods/patient group: Study subjects prescribed losartan, an ACE inhibitor or a calcium channel antagonist were identified from prescriptions in hospital or community pharmacies. Events and other information were collected from doctors and pharmacists by mailed questionnaires. Events were coded and analysed using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Crude event rates were calculated and compared between patients treated with losartan and those receiving control drugs. When the difference was statistically significant, the event was further examined in several ways, including follow-up studies and by comparison with the data of the UK PEM study on losartan. Results: Pharmacists were sent 4344 questionnaires and returned 3591 (83%), while doctors were sent 3517 questionnaires and returned 1380 (39%). In the doctors' data, the adverse event rate for losartan treatment was greater than that for ACE inhibitors and/or calcium channel antagonists for the following seven events: headache, palpitations, anaemia, insomnia, feeling abnormal, increased blood pressure and asthma. Most of these are known adverse drug reactions (ADRs) of losartan except for two events: increased blood pressure and asthma. In pharmacists' data, the event rate for losartan was significantly greater than that for control drugs for the following ten events: hot flushes, abnormal hepatic function, oedema, peripheral swelling, decreased blood pressure, increased blood pressure, rhinitis, contact dermatitis, dry skin and heat rash. The first five events were known ADRs of losartan but the other five were not. When the two sets of data were combined, the rate of an additional event, increased blood creatinine phosphokinase, which is a known ADR of losartan, was significantly greater than that for the control drugs. The six events that were not documented as ADRs for losartan were not judged to be ADRs based on the results of follow-up studies and comparison with the UK PEM study on losartan. The crude rate of cough with losartan treatment was similar to that with calcium channel antagonists, but was significantly less than that with ACE inhibitors. Conclusion: No novel safety problems were found in this observational cohort study on losartan. The rates of some known ADRs differed significantly between patients treated with losartan and those in the control groups.

Original languageEnglish
Pages (from-to)811-821
Number of pages11
JournalDrug Safety
Volume25
Issue number11
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Losartan
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Prescriptions
Japan
Monitoring
Drug-Related Side Effects and Adverse Reactions
Blood pressure
Pharmaceutical Preparations
Drug and Narcotic Control
Pharmacists
Blood Pressure
1,4-dihydropyridine
Medical Dictionaries
Cohort Studies
Asthma
Dermatitis
Pharmacies
Contact Dermatitis
Sleep Initiation and Maintenance Disorders

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Samizo, K., Kawabe, E., Hinotsu, S., Sato, T., Kageyama, S., Hamada, C., ... Kubota, K. (2002). Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: A pilot study of prescription-event monitoring in Japan. Drug Safety, 25(11), 811-821.

Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists : A pilot study of prescription-event monitoring in Japan. / Samizo, K.; Kawabe, E.; Hinotsu, S.; Sato, T.; Kageyama, S.; Hamada, C.; Ohashi, Y.; Kubota, K.

In: Drug Safety, Vol. 25, No. 11, 2002, p. 811-821.

Research output: Contribution to journalArticle

Samizo, K, Kawabe, E, Hinotsu, S, Sato, T, Kageyama, S, Hamada, C, Ohashi, Y & Kubota, K 2002, 'Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: A pilot study of prescription-event monitoring in Japan', Drug Safety, vol. 25, no. 11, pp. 811-821.
Samizo, K. ; Kawabe, E. ; Hinotsu, S. ; Sato, T. ; Kageyama, S. ; Hamada, C. ; Ohashi, Y. ; Kubota, K. / Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists : A pilot study of prescription-event monitoring in Japan. In: Drug Safety. 2002 ; Vol. 25, No. 11. pp. 811-821.
@article{12f399629d1344188cf4d60e18beae2c,
title = "Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: A pilot study of prescription-event monitoring in Japan",
abstract = "Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE inhibitors and dihydropyridine calcium channel antagonists. Study design: We conducted a cohort study with a concurrent control. Methods/patient group: Study subjects prescribed losartan, an ACE inhibitor or a calcium channel antagonist were identified from prescriptions in hospital or community pharmacies. Events and other information were collected from doctors and pharmacists by mailed questionnaires. Events were coded and analysed using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Crude event rates were calculated and compared between patients treated with losartan and those receiving control drugs. When the difference was statistically significant, the event was further examined in several ways, including follow-up studies and by comparison with the data of the UK PEM study on losartan. Results: Pharmacists were sent 4344 questionnaires and returned 3591 (83{\%}), while doctors were sent 3517 questionnaires and returned 1380 (39{\%}). In the doctors' data, the adverse event rate for losartan treatment was greater than that for ACE inhibitors and/or calcium channel antagonists for the following seven events: headache, palpitations, anaemia, insomnia, feeling abnormal, increased blood pressure and asthma. Most of these are known adverse drug reactions (ADRs) of losartan except for two events: increased blood pressure and asthma. In pharmacists' data, the event rate for losartan was significantly greater than that for control drugs for the following ten events: hot flushes, abnormal hepatic function, oedema, peripheral swelling, decreased blood pressure, increased blood pressure, rhinitis, contact dermatitis, dry skin and heat rash. The first five events were known ADRs of losartan but the other five were not. When the two sets of data were combined, the rate of an additional event, increased blood creatinine phosphokinase, which is a known ADR of losartan, was significantly greater than that for the control drugs. The six events that were not documented as ADRs for losartan were not judged to be ADRs based on the results of follow-up studies and comparison with the UK PEM study on losartan. The crude rate of cough with losartan treatment was similar to that with calcium channel antagonists, but was significantly less than that with ACE inhibitors. Conclusion: No novel safety problems were found in this observational cohort study on losartan. The rates of some known ADRs differed significantly between patients treated with losartan and those in the control groups.",
author = "K. Samizo and E. Kawabe and S. Hinotsu and T. Sato and S. Kageyama and C. Hamada and Y. Ohashi and K. Kubota",
year = "2002",
language = "English",
volume = "25",
pages = "811--821",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "11",

}

TY - JOUR

T1 - Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists

T2 - A pilot study of prescription-event monitoring in Japan

AU - Samizo, K.

AU - Kawabe, E.

AU - Hinotsu, S.

AU - Sato, T.

AU - Kageyama, S.

AU - Hamada, C.

AU - Ohashi, Y.

AU - Kubota, K.

PY - 2002

Y1 - 2002

N2 - Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE inhibitors and dihydropyridine calcium channel antagonists. Study design: We conducted a cohort study with a concurrent control. Methods/patient group: Study subjects prescribed losartan, an ACE inhibitor or a calcium channel antagonist were identified from prescriptions in hospital or community pharmacies. Events and other information were collected from doctors and pharmacists by mailed questionnaires. Events were coded and analysed using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Crude event rates were calculated and compared between patients treated with losartan and those receiving control drugs. When the difference was statistically significant, the event was further examined in several ways, including follow-up studies and by comparison with the data of the UK PEM study on losartan. Results: Pharmacists were sent 4344 questionnaires and returned 3591 (83%), while doctors were sent 3517 questionnaires and returned 1380 (39%). In the doctors' data, the adverse event rate for losartan treatment was greater than that for ACE inhibitors and/or calcium channel antagonists for the following seven events: headache, palpitations, anaemia, insomnia, feeling abnormal, increased blood pressure and asthma. Most of these are known adverse drug reactions (ADRs) of losartan except for two events: increased blood pressure and asthma. In pharmacists' data, the event rate for losartan was significantly greater than that for control drugs for the following ten events: hot flushes, abnormal hepatic function, oedema, peripheral swelling, decreased blood pressure, increased blood pressure, rhinitis, contact dermatitis, dry skin and heat rash. The first five events were known ADRs of losartan but the other five were not. When the two sets of data were combined, the rate of an additional event, increased blood creatinine phosphokinase, which is a known ADR of losartan, was significantly greater than that for the control drugs. The six events that were not documented as ADRs for losartan were not judged to be ADRs based on the results of follow-up studies and comparison with the UK PEM study on losartan. The crude rate of cough with losartan treatment was similar to that with calcium channel antagonists, but was significantly less than that with ACE inhibitors. Conclusion: No novel safety problems were found in this observational cohort study on losartan. The rates of some known ADRs differed significantly between patients treated with losartan and those in the control groups.

AB - Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE inhibitors and dihydropyridine calcium channel antagonists. Study design: We conducted a cohort study with a concurrent control. Methods/patient group: Study subjects prescribed losartan, an ACE inhibitor or a calcium channel antagonist were identified from prescriptions in hospital or community pharmacies. Events and other information were collected from doctors and pharmacists by mailed questionnaires. Events were coded and analysed using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. Crude event rates were calculated and compared between patients treated with losartan and those receiving control drugs. When the difference was statistically significant, the event was further examined in several ways, including follow-up studies and by comparison with the data of the UK PEM study on losartan. Results: Pharmacists were sent 4344 questionnaires and returned 3591 (83%), while doctors were sent 3517 questionnaires and returned 1380 (39%). In the doctors' data, the adverse event rate for losartan treatment was greater than that for ACE inhibitors and/or calcium channel antagonists for the following seven events: headache, palpitations, anaemia, insomnia, feeling abnormal, increased blood pressure and asthma. Most of these are known adverse drug reactions (ADRs) of losartan except for two events: increased blood pressure and asthma. In pharmacists' data, the event rate for losartan was significantly greater than that for control drugs for the following ten events: hot flushes, abnormal hepatic function, oedema, peripheral swelling, decreased blood pressure, increased blood pressure, rhinitis, contact dermatitis, dry skin and heat rash. The first five events were known ADRs of losartan but the other five were not. When the two sets of data were combined, the rate of an additional event, increased blood creatinine phosphokinase, which is a known ADR of losartan, was significantly greater than that for the control drugs. The six events that were not documented as ADRs for losartan were not judged to be ADRs based on the results of follow-up studies and comparison with the UK PEM study on losartan. The crude rate of cough with losartan treatment was similar to that with calcium channel antagonists, but was significantly less than that with ACE inhibitors. Conclusion: No novel safety problems were found in this observational cohort study on losartan. The rates of some known ADRs differed significantly between patients treated with losartan and those in the control groups.

UR - http://www.scopus.com/inward/record.url?scp=0036398302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036398302&partnerID=8YFLogxK

M3 - Article

C2 - 12222991

AN - SCOPUS:0036398302

VL - 25

SP - 811

EP - 821

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 11

ER -